SSRIs vs. Psilocybin: Is Big Pharma Out to Get Us?

Citations:
Forsman, J., Masterman, T., Ahlner, J., Isacsson, G., & Hedström, A. K. (2019). Selective serotonin re-uptake inhibitors and the risk of violent suicide: a nationwide postmortem study. European journal of clinical pharmacology, 75(3), 393-400. https://link.springer.com/article/10.1007/s00228-018-2586-2
Stübner, S., Grohmann, R., Greil, W., Zhang, X., Müller-Oerlinghausen, B., Bleich, S., ... & Neyazi, A. (2018). Suicidal ideation and suicidal behavior as rare adverse events of antidepressant medication: current report from the AMSP multicenter drug safety surveillance project. International journal of neuropsychopharmacology, 21(9), 814-821. https://academic.oup.com/ijnp/article-abstract/21/9/814/5043110
Hengartner, M. P., Amendola, S., Kaminski, J. A., Kindler, S., Bschor, T., & Plöderl, M. (2021). Suicide risk with selective serotonin reuptake inhibitors and other new-generation antidepressants in adults: a systematic review and meta-analysis of observational studies. J Epidemiol Community Health.
Duman, R. S. (2018). Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide. F1000Research, 7. https://jech.bmj.com/content/early/2021/03/07/jech-2020-214611.abstract
Klein, M. E., Chandra, J., Sheriff, S., & Malinow, R. (2020). Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents. Proceedings of the National Academy of Sciences, 117(5), 2656-2662. https://www.pnas.org/content/117/5/2656.short
Williams, N. R., Heifets, B. D., Bentzley, B. S., Blasey, C., Sudheimer, K. D., Hawkins, J., ... & Schatzberg, A. F. (2019). Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism. Molecular psychiatry, 24(12), 1779-1786. https://www.nature.com/articles/s41380-019-0503-4
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., ... & Griffiths, R. R. (2020). Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA psychiatry. https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2772630
Hendricks, P. S., Johnson, M. W., & Griffiths, R. R. (2015). Psilocybin, psychological distress, and suicidality. Journal of Psychopharmacology, 29(9), 1041-1043. https://journals.sagepub.com/doi/full/10.1177/0269881115598338
Zeifman, R. J., Wagner, A. C., Watts, R., Kettner, H., Mertens, L. J., & Carhart-Harris, R. L. (2020). Post-psychedelic reductions in experiential avoidance are associated with decreases in depression severity and suicidal ideation. Frontiers in Psychiatry, 11, 782. https://www.frontiersin.org/articles/10.3389/fpsyt.2020.00782/full?utm_source=S-TWT&utm_medium=SNET&utm_campaign=ECO_FPSYT_XXXXXXXX_auto-dlvrit
Tondo, L., & Baldessarini, R. J. (2018). Antisuicidal effects in mood disorders: are they unique to lithium?. Pharmacopsychiatry, 51(05), 177-188. http://psychiatry.aok.pte.hu/tavoktatas/Tondo_Lithium%20antisuicide.pdf

TIMESTAMPS (Jax):
0:00 Introduction
1:11 Why Leo made this video
3:02 SSRIs and suicidal ideation
5:17 Why SSRIs may increase suicide risk
5:22 Psilocybin, Cabergoline, and Pramipexole
5:58 increase in neurogenesis
7:45 Inhibition of dopaminergic function
8:49 How long SSRIs take to work
9:09 SSRI side effects
9:32 Starting with micro doses
10:27 Why Leo is speaking on this subject
11:41 Why do SSRIs work for some people and not others?
11:48 Metabolism polymorphisms
12:18 Polymorphisms in the promoter region of your SERT transporter
13:03 Polymorphisms in Serotonin receptors
13:30 Polymorphisms that affect you long term
13:52 Do other drugs not enhance suicide risk?
13:54 Ketamine
15:17 What Ketamine does
16:17 Psilocybin as a short term antidepressant
17:04 Psychedelics
18:20 Lithium and suicidality
19:23 Risks of Lithium
20:06 What is Psychiatry?
20:54 SSRIs
21:55 Why do people stop SSRIs
22:56 Big pharma incentives
23:52 Hurdles for big pharma
24:06 Cardiovascular disease studies
25:43 SSRIs vs Psilocybin
26:41 Why Leo tends to prefer SSRIs
27:45 Cerebral Lysine
28:39 SSRI safety profiles
29:16 Increase in neurogenesis and reduction in neuro inflammation
30:00 SSRIs for performance enhancement
30:45 SSRIs and Psilocybin
31:21 Leo on demonizing SSRIs
32:10 Leo and his father’s cognitive architecture
33:27 Leo restating why he made this video

👉🏻 Ways to support and save (affiliate links):
- LA Pump: https://lapump.com/?wpam_id=13 Get 10% OFF with code LONGLEO
- Nurosym: https://nurosym.com Discount Code: LucieC5
-CosmicNootropic: https://cosmicnootropic.com?coupon-code=319 Get 10% OFF with code LUCIE
- Amazon Store: Shop items Leo personally recommended and used https://www.amazon.com/shop/leoandlongevity?ref=ac_inf_tb_vh

🔗 Connect & Explore 🔗
JOIN THE COMMUNITY:
Reddit ▶ The Long-Lived Community / thelonglived
Telegram ▶ https://t.me/+k4x31DY9tgIwM2Fh
TikTok ▶ https://www.tiktok.com/@leoandlongevity?_t=8hXP1SML0LG&_r=1
GENETIC ANALYSIS WAITLIST: Website ▶ https://www.yourgenetically.com/
OTHER CHANNELS
Lucie ▶ / @luciec.7692
Kids ▶ / @bilinguini

🏷️ Leo's personal book collection now on eBay: https://www.ebay.com/usr/colous7

🌍 Together, Let’s Continue Leo's Legacy In the spirit of Leo's passion for health, wellness, and a life well-lived, let’s continue to explore, learn, and journey through the fascinating world of biohacking, fitness, and cognitive wellness. Your presence here is not just a subscription; it's a torchbearer of Leo's legacy, ensuring his light continues to shine, guide, and inspire future generations.